Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MEDSIR","sponsor":"Debiopharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MEDSIR & Debiopharm Explore Synergy of Debio 0123 & Sacituzumab in Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by MEDSIR

    Menu

    MEDSIR

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MEDSIR

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Spain
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MEDSIR & Debiopharm Explore Synergy of Debio 0123 & Sacituzumab in Breast Cancer

              Details:

              The collaboration aims to evaluate the safety and efficacy of Debio 0123, Debiopharm's investigational, potential best-in-class WEE1 inhibitor, together with Trodelvy (sacituzumab govitecan).

              Lead Product(s): Debio 0123,Sacituzumab Govitecan

              Therapeutic Area: Oncology Product Name: Debio 0123

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Debiopharm

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 28, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY